Inflammatix is developing the TriVerity™ test, which utilizes immune response profiling through mRNA analysis to differentiate between bacterial and viral infections in emergency department patients. This technology addresses the challenge of accurately diagnosing acute infections and sepsis, enabling timely clinical decisions and potentially reducing ICU admissions.
Funding
$213.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Emergency department physicians often struggle to accurately diagnose acute infections and sepsis, leading to uncertainty in treatment decisions for patients suspected of these conditions. Current diagnostic methods can be slow or lack the precision needed to differentiate between bacterial, viral, and non-infectious etiologies. This diagnostic uncertainty can result in delayed or inappropriate treatment, potentially increasing ICU admissions and healthcare costs.
Solution
Inflammatix is developing the TriVerity™ test, a host-response diagnostic that analyzes mRNA signatures to rapidly distinguish between bacterial and viral infections in emergency department patients. By interpreting the patient's immune response, the TriVerity™ test aims to provide clinicians with actionable information to guide treatment decisions. The test is designed to identify patients who are likely to require ICU-level intervention, enabling timely and appropriate care. Inflammatix leverages expertise in bioinformatics, machine learning, and molecular biology to develop diagnostics that help physicians make confident and timely clinical decisions.
Target Audience
The primary target audience is emergency medicine physicians who evaluate patients suspected of acute infection and sepsis.
Features
- mRNA analysis of the patient's immune response to differentiate between bacterial, viral, and non-infectious conditions.
- Machine learning algorithms to interpret complex immune signatures.
- Identification of patients at high risk for requiring ICU-level intervention.
- Results available in a clinically relevant timeframe to guide treatment decisions.